Secreted bioactive factors from Bifidobacterium infantis enhance epithelial cell barrier function

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 295, Issue 5, 2008, Pages

  Ewaschuk, Julia B ^a   Diaz, Hugo ^a   Meddings, Liisa ^a   Diederichs, Brendan ^a   Dmytrash, Andrea ^a   Backer, Jody ^a   Langen, Mirjam Looijer Van ^a   Madsen, Karen L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Bifidobacterium sp; Cytokine; Interleukin 10; Intestine; Permeability; Probiotics; Tight junctions

Indexed keywords

CLAUDIN 1; CLAUDIN 2; CLAUDIN 3; CLAUDIN 4; GAMMA INTERFERON; INTERLEUKIN 10; MITOGEN ACTIVATED PROTEIN KINASE; OCCLUDIN; PROTEIN ZO1; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM LONGUM INFANTIS; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; HISTOPATHOLOGY; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TIGHT JUNCTION;

ANIMALS; BIFIDOBACTERIUM; CELL LINE, TUMOR; CULTURE MEDIA, CONDITIONED; GENE DELETION; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-10; INTESTINES; MEMBRANE PROTEINS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; PROBIOTICS;

EID: 57349107080     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90227.2008     Document Type: Article

References (49)

1. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 35: 1163-1169, 2000.
2. Beisswenger C, Coyne CB, Shchepetov M, Weiser JN. Role of p38 MAP kinase and transforming growth factor-beta signaling in transepithelial migration of invasive bacterial pathogens. J Biol Chem 282: 28700-28708, 2007.
3. Besselink M, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo-controlled trial. Lancet 371: 651-659, 2008.
4. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkin AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function in an apoptosis-independent mechanism. J Immunol 171: 6164-6172, 2003.
5. Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex. Ann NY Acad Sci 1072: 242-252, 2006.
6. Clarkson T. Measurement of short-circuit current and ion transport across the ileum. Am J Physiol 206: 658-668, 1964.
7. De Groote MA, Frank DN, Dowell E, Glode MP, Pace NR. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 24: 278-280, 2005.
8. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora [see comment]. Science 308: 1635-1638, 2005.
9. Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 9: 143-151, 2003.
10. Frank D, Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104: 13780-13785, 2007.
11. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 66: 307-315, 2007.
12. Howe KL, Reardon C, Wang A, Nazli A, McKay DM. Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157: H7-induced increased permeability. Am J Pathol 167: 1587-1597, 2005.
13. Ishibashi N, Yamazaki S. Probiotics and safety. Am J Clin Nutr 73: 465S-470S, 2001.
14. Jijon HB, Panenka WJ, Madsen KL, Parsons HG. MAP kinases contribute to IL-8 secretion by intestinal epithelial cells via a posttranscriptional mechanism. Am J Physiol Cell Physiol 283: C31-C41, 2002.
15. Kennedy RJ, Hoper M, Deodhar K, Erwin PJ, Kirk SJ, Gardiner KR. Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br J Surg 87: 1346-1351, 2000.
16. Kyosseva SV. Mitogen-activated protein kinase signaling. Int Rev Neurobiol 59: 201-220, 2004.
17. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy [see comment]. Pediatrics 115: 178-181, 2005.
18. Lee SJ, Cho SJ, Park EA. Effects of probiotics on enteric flora and feeding tolerance in preterm infants. Neonatology 91: 174-179, 2007.
19. Li Q, Zhang Q, Wang M, Zhao Ma J, Luo N, Li N, Li Y, Xu G, Li J. Interferon and tumor necrosis factor disrupt epithelial barrier function by altering lipid composition in membrane microdomains of tight junction. Clin Immunol 126: 67-80, 2008.
20. Madara JL, Stafford J. Interferon-gamma directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest 83: 724-727, 1989.
21. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121: 580-591, 2001.
22. Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice [comment]. Gastroenterology 116: 1107-1114, 1999.
23. Madsen KL, Fedorak RN, Tavernini MM, Doyle JS. Normal breast milk limits the development of colitis in IL-10-deficient mice. Inflamm Bowel Dis 8: 390-398, 2002.
24. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN. Interleukin-10 gene-deficient mice develop a primary intestinal permeability defect in response to enteric microflora. Inflamm Bowel Dis 5: 262-270, 1999.
25. Menard S, Candalh C, Bambou JC, Terpend K, Cerf-Bensussan N, Heyman M. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 53: 821-828, 2004.
26. Mitra P, Keese CR, Giaever I. Electric measurements can be used to monitor the attachment and spreading of cells in tissue culture. Biotechniques 11: 504-510, 1991.
27. Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, Vecchio FM, Gasbarrini A, Gasbarrini G. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 69: 225-228, 2004.
28. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101: 428-435, 1995.
29. Nusrat A, Turner JR, Madara JL. Molecular physiology and pathophysiology of tight junctions. IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells. Am J Physiol Gastrointest Liver Physiol 279: G851-G857, 2000.
30. O'Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep 7: 688-693, 2006.
31. Oshitani N, Watanabe K, Nakamura S, Fujiwara Y, Higuchi K, Arakawa T. Dislocation of tight junction proteins without F-actin disruption in inactive Crohn's disease. Int J Mol Med 15: 407-410, 2005.
32. Petrof EO, Kojima K, Ropeleski MJ, Musch MW, Tao Y, De Simone C, Chang EB. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127: 1474-1487, 2004.
33. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, Collins JE. Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial cells. Lab Invest 85: 1139-1162, 2005.
34. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 52: 988-997, 2003.
35. Seth A, Yan F, Polk DB, Rao RK. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PCK and MAP kinase dependent mechanism. Am J Physiol Gastrointest Liver Physiol 294: G1060-G1069, 2008.
36. Shen TY, Qin HL, Gao ZG, Fan XB, Hang XM, Jiang YQ. Influences of enteral nutrition combined with probiotics on gut microflora and barrier function of rats with abdominal infection. World J Gastroenterol 12: 4352-4358, 2006.
37. Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 19: 308-315, 2004.
38. Sydora BC, Tavernini MM, Doyle JS, Fedorak RN. Association with selected bacteria does not cause enterocolitis in IL-10 gene-deficient mice despite a systemic immune response. Dig Dis Sci 50: 905-913, 2005.
39. Sydora BC, Tavernini MM, Wessler A, Jewell LD, Fedorak RN. Lack of interleukin-10 leads to intestinal inflammation, independent of the time at which luminal microbial colonization occurs. Inflamm Bowel Dis 9: 87-97, 2003.
40. Tao Y, Drabik KA, Waypa TS, Musch MW, Alverdy JC, Schneewind O, Chang EB, Petrof EO. Soluble factors from Lactobacillus GG activate MAPKs and induce cytoprotective heat shock proteins in intestinal epithelial cells. Am J Physiol Cell Physiol 290: C1018-C1030, 2006.
41. Turner JR. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 169: 1901-1909, 2006.
42. Ukena S, Singh A, Dringenberg U, Engelhardt R, Seidler U, Hansen W, Bleich A, Bruder D, Franzke A, Rogler G, Suerbaum S, Buer J, Gunzer F, Westendorf A. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS Biol 2: e1308, 2007.
43. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Annu Rev Physiol 68: 403-429, 2006.
44. Wagner RD, Warner T, Roberts L, Farmer J, Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect Immun 65: 3345-3351, 1997.
45. Watson CJ, Hoare CJ, Garrod DR, Carlson GL, Warhurst G. Interferon-gamma selectively increases epithelial permeability to large molecules by activating different populations of paracellular pores. J Cell Sci 118: 5221-5230, 2005.
46. Xavier R, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434, 2007.
47. Yan F, Cao H, Cover TL, Whitehead R, Washington MK, Polk DB. Soluble proteins produced by probiotic bacteria regulate intestinal epithelial cell survival and growth. Gastroenterology 132: 562-575, 2007.
48. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease [see comment]. Gut 56: 61-72, 2007.
49. Zyrek AA, Cichon C, Helms S, Enders C, Sonnenborn U, Schmidt MA. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 9: 804-816, 2007.